Epidiolex /mL
Phase 3Small molecule
Jazz PharmaceuticalsEpidiolex /mL is one of 16 small molecule programs targeting Dravet Syndrome (DS). It is currently in Phase 3.
3
Indications
5
Total Trials
3
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Buprenorphine
#DrugCompanyPhaseTrials
1Suboxone
IIndivior Inc.
Approved
Buprenorphine/naloxone
AstellasPhase 3
Marinol
Jazz PharmaceuticalsPhase 3
Lucemyra
BBioCorRx Pharmaceuticals Inc
Phase 2
Epidiolex /mL
Jazz PharmaceuticalsPhase 3
XR-B
NNYU Langone Health
Phase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kaletra
GSKPreclinical
Buprenorphine Control
WWashington University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Buprenorphine1 trial
Dental Pain1 trial
CBD for Dental Pain
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT04642404·64 enrolled
Tuberous Sclerosis1 trial
Dravet Syndrome (DS)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epidiolex /mL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company